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Erythropoietin (Epo) is a true hematopoietic hor-
mone produced in response to lowered oxygen ten-
sion. The liver is the main source of Epo during 
most of fetallife, but the liver to kidney switch oc-
curs around birth so that 90% of Epo synthesis 
takes place in the kidney very soon in life. E!evated 
serum Epo levels are observed at birth in the case of 
maternaI hypertension, akoholism, or diabetes 
mellitus, in the presence of Rh immunization or se-
vere growth retardation, or after ~-sympathomi­
metic tocolysis, ail situations associated with fetal 
hypoxia. On the other hand, Epo production may 
be found to be inadequate for the degree of anemia 
in a variety of conditions, including renai failure, 
juvenile rheumatoid arthritis, acquired immune 
deficiency syndrome, surgery, cancer, chemother-
apy, marrow transplantation, and prematurity. The 
pathophysiology of the anemia of prematurity is 
complex, but the most prominent feature is de-
fective Epo synthesis in response to the anemia. 
In view of the risks associated with blood trans-
fusions, recombinant human erythropoietin 
(rHuEpo) has been proposed to treat the anemia of 
prematurity. The results appear to be promising, 
but further information is needed about the perti-
nent indications, the best dosage, timing, and route 
of administration of rHuEpo, as weil as the appro-
priate method of iron supplementation. Patients 
with many other dinical disorders may benefit 
from rHuEpo therapy, but with the exception of the 
anemia of chronic renal failure the exact role of Epo 
in their management remains undefined at the pre-
senttime. 
Corresponding author: Yves Beguin, M.D., University of Liège, 
Departrnent of Hematology, CHU Sart-Tilman, 4000 Liège, 
Belgium. 
Key words: erythropoietin, erythropoiesis, anemia of 
prematurity, infant child, recombinant human erythro-
poietin 
Epo is heavily a glycosylated protein formed of 165 
amino acids with a molecular mass of 34,000 Da. 
Except during fetallife, Epo is mostly produced by the 
kidney, but the exact cell of origin remains unknown. 
Ten percent of Epo production is also contributed by 
other organs, rnainly the liver in which limîted produc-
tion capacity does not allow an aclequate response to 
hypoxia. There are no preformed stores of Epo and any 
increase in the rate of production must be preceded by 
Epo gene transcription.1 Epo production is regulated 
by a feedback mechanism by which the blood oxygen 
content is maintained at a constant level through the 
function of a kidney oxygen sensor. 2 The major deter-
minant of Epo production is therefore the circulating 
red cell mass, but other factors also play a role, includ-
ing kidney oxygen consumption, renal blood flow, oxy-
gen saturation (mostly dependent on pulmonary 
function), and oxygen affinity of hemoglobin. 
Epo ,exerts its action on target cells after binding to a 
specifie Epo receptor whose structure and function 
have been extensively studied.3 Both high-affinity and 
low-affinity receptors are present at the surface of ery-
throid cells (except mature red cells). Mouse and 
human placentas have low-affinity Epo receptors' The 
peak receptor number is reached at the colony-forming 
unit-erythrocyte (CFU-E) stage, but Epo is necessary 
for the survival, proliferation, and differentiation of 
burst-forming unit-erythrocyte (BFU-E), CFU-E, and 
erythroblasts. 
It is not the purpose of this review to detail the gen-
eral physiology of Epo in man, whieh has been reviewed 
in other excellent articles.5,6 Therefore, only the major 
features of Epo will be outIined here. We will discuss 
more thoroughly the specifie aspects of Epo in infants 
and children, including the biology of the hormone and 
the therapeutic uses of recombinant human erythropoi-
etin (rHuEpo). We will in particular address the phys-
iopathology and treatment of the anemia of prematurity 
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PHYSIOLOGY OF ERYTHROPOIESIS 
AND ERYTHROPOIETIN IN THE FETUS 
ANDNEONATE 
Erythropoiesis undergoes a rernarkable evolution 
throughout gestation and the neonatal periodJ,8 
Hematopoiesis restricted ta erythropoiesis begins in 
the yolk sac around day 14 of gestation. Fetal 
hematopoiesis begins primarily in the liver and secon-
darily in the spleen, between weeks 6 and 8 of gesta-
tion. Hepatic erythropoiesis decreases and marrow 
erythropoiesis Încreases during the second trimes ter, 50 
that after birth the marrow remains the only erythro-
poietic organ.' Fetal erythropoiesis is contro11ed by 
Epo, particularly during the second half of gestation.10 
Epo receptors are found in mouse fetalliver. l1 
In several animal species, fetal Epo is synthesized 
primarily in the liver. Bilateral nephrectomy has no ef-
fect on the fetal Epo response to hypoxia induced by 
bleeding of pregnant goats.12 In fetal sheep, it is the liver 
that has been shown to be the primary site of Epo for-
mation until late in gestation.13,14 The liver ta kidney 
switch appears to begin in the third trimester and ends 
approximately 6 weeks after birth.14 This explains why 
subtotal hepatectomy, but not bilateral nephrectomy, 
inhibited the Epo response to acute bleeding.13 The liver 
to kidney switch appears to tak,e place at the end of ges-
tation in rnice also, as fetalliver produces Epo up ta clay 
18 of gestation but no longer by day 19 when Epo 
rnRNA can be detected in the kidney in the presence of 
anemia.15 The rat fetus appears ta have extrahepatic 
Epo before day 17 of gestation, fo11owed by hepatic and, 
ta a lesser extent, renal Epo production, bath of which 
become sensitive ta maternaI hypoxia during the last 
days of pregnancy.l6 The liver to kidney switch appears 
to take place after birth,17 around day 10 in normal con-
ditions, but as early as day 2 in hypoxic conditions.16 
Indirect evidence of the postnatal switch from liver to 
kidney Epo production is also available in humans. 
Infants born with severe renal disease have Epo leveis 
and erythropoietic activities similar to those of normal 
infants.l8 A blunted Epo response to anemia in the fetus 
may be explained by the decreased sensitivity of the 
liver to hypoxia as compared with the kidney.1' 
SERUM EPO IN ADULTS 
In adults, serum Epo levels may vary considerably.6 
Levels are usua11y between 10 and 20 mU Iml in normal 
subjects, may decrease somewhat in primary poly-
cythemia, but increase exponentially when anemia de-
velops below Hct of 30-35%. Therefore, a serum Epo 
value must always be evaluated in relation to the de-
gree of anemia. Serum Epo levels can be inappropri-
ately high in secondary polycythemia, a feature 
permitting its diagnostic separation from primary 
polycythemia20 Epo levels inappropriately low for the 
degree of anemia (Table 1) are encountered not only in 
renal failure,21 but also in a number of other conditions, 
including the anemia of chronic disorders.22 Accord-
ingly, inadequate Epo production has been found to 
contribute to the anemia of rheumatoid arthritisp 
human immunodeficiency virus infection,24 or cancer.25 
Intensive chemotherapy, whether followed by bone 
marrow transplantation or not, may cause a transient 
elevation of serum Epo levels.26,27 However, in the long 
run, chemotherapy with cis-platinum28 and a110geneic 
bone marrow transplantation26,27 are associated with 
inappropriately low Epo levels, in part caused by renal 
impairment. Renal dysfunction is also a contributing 
factor for low Epo levels in multiple myeloma.29 Serum 
Epo levels, although increased over nonpregnant val-
ues, remain relatively low for the degree of anemia in 
the first part of pregnancy but retum progressively to 
adequate levels thereafter.3° 
SERUM EPO IN FETUS AND NEONATE 
Relatively low levels of immunoreactive Epo can be de-
tected in fetal plasma from week 16 of pregnancy.3lJ2 
While a continuous increase of Hb is observed during 
gestation,31 a correlation of Epo levels with gestational 
age was found in some32 but not other31 studies. 
Although this has been observed in sorne studies,33,34 
fetal Epo levels are usua11y not different in preterm as 
compared to term infants.35,36 Labor can induce signifi-
cant elevations of cord blood Epo levels37--40 even if this 
has not been observed in a11 studies.4l Altogether, fetal 
Epo levels in uncomplicated pregnancies before as weIl 
as after labor will usua11y not increase above 50 
mUjml.35,42,43 
Neither during pregnancy32 nor at birth36,43 is there a 
significant correlation between serum Epo and Hb. 
However, when an anemia develops, as in the case of 
Rh immunization, a significant inverse relationship is 
evident.40,44A5 In the case of diabetes mellitus, in which 
the hypoxia is not secondary ta anemia, there is even a 
positive correlation between serum Epo and Hb that 
explains the polycythemia.46 Although this is not ob-
TABLE 1 




Chronic renal failure 
Anemia of chronic disorder 
Cancer (solid tumors, multiple myeloma) 
Rheumatoid arthritis 
Infectious diseases (AIDS) 
Surgery 
Chemotherapy with cisplatinum 
Allogeneic bone marrow transplantation 
Early pregnancy 
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served in a normal uncomplicated pregnancy,32 there is 
a good correlation between serum Epo and erythrob-
last counts in the case of chronic fetai hypoxia.44,46--49 
At the end of pregnancy, either before labor or just 
after birth, there is usually a strong inverse correlation 
of serum Epo with card blood pH,33,35,36,39,43--45,47,48 but 
usually not with cDrd blood PaOz.32,35,43--45 Accord-
ingly, a number of situations have been associated 
with elevated fetal Epo levels (Table II). Hypertension 
with or without pre-eclampsia is one of thern,39,43.505 1 
but elevated Epo levels after pre-eclamptic pregnancy 
rapidly resolve after birth.50 Intravenous ~-sympath­
omimetic tocolysis stimulates fetal Epo production, 
possibly by decreasing fetal oxygenation through 
alterations of metabolism and/or decreased placental 
blood flow.52 Increased Epo levels are observed in 
fetuses with severe growth retardation.35,39,47 PetaI 
distress causes a significant elevation of cord blood 
EpO,33,35,36,44,53 even if this has not been shown in aIl 
studies.39 This discrepancy may be due to the fact that, 
contrary to chronic hypoxia,35,47,50 acute hypoxia was 
not always sufficient for inducing increased Epo 
synthesis.39 While vasopressin and hypoxanthine are 
beller indicators of acute hypoxia,39 high Epo levels 
after normal pregnancies, but not after pre-ecla'mpsia, 
indicate an increased risk of perinatal brain damage.51 
MaternaI alcohoi abuse is also accompanied by 
elevated fetai Epo leveis that correlate with maternaI 
alcohol intake, but it is not clear whether this is a 
direct effect of ethanol or is induced by chronic fetal 
hypoxia.53 
Rh isoimmunization resuits in fetai anemia from red 
blood cell destruction, and this anemia is partIy com-
pensated for by extramedullary hematopoiesis and 
erythroblastosis. Amniotic fluid and umbilical blood 
obtained by cordocentesis as weIl as at birth contain eI-
evated Epo levels.40,44,45,48 However, this increase in Epo 
production is minimal before week 20 or 24 of gesta-
tion40,48 and takes place only in the presence of severe 
fetal anemia.48 One can observe a strong inverse corre-
lation between serum Epo and Hb, as weIl as a strong 
positive correlation between Epo and erythrob-
lasts.4O•44.45.48 Elevated Epo levels can thus predict fetal 
distress and indeed correlate directly with fetal heart 
rate54 and inversely with blood pH at birth.44.45,48 
TABLE II 
Conditions Associated with Elevated Epo Levels 
at Birth 
Labor 
Intravenous ~-sympathomimetic tocolysis 
Severe growth retardation 
MaternaI hypertension (with or without pre-eclampsia) 
MaternaI diabetes mellitus 
MaternaI alcoholism 
Rhesus immunization (with anemia) 
MaternaI diabetes mellitus causes fetal poly-
cythemia and thrombocytopenia in proportion to the 
maternaI glycosylated Hb percentage.55 Although the 
number of CFU-E may be increased,56 the number of 
BFU-E and their growth in the presence of Epo appear 
to be normal. 56•57 Il is thus suggested that polycythemia 
is an adaptive response in infants of diabetic mothers. 
MaternaI hyperglycemia induces fetal hyperglycernia, 
which in turn stimulates insulin secretion by the fetus. 
The resulting increased metabolism causes tissue hy-
poxia and acidemia that are thought to be responsible 
for increased Epo production.4M9,58 Indeed fetal Epo 
correlates directly with fetai insulin.49 Antepartum con-
trol of maternaI hyperglycemia is critical, as elevated 
fetal Epo levels are observed in patients with poorly 
controIled diabetes46,49,58 but not in patients with good 
glycemic contro1.57 However, not aIl the elevation of 
erythropoietic activity can be accounted for by in-
creased Epo production and other factors could con-
tribute, including insulin itsell.'6.s' 
SERUM EPO IN CHILDREN 
While serum Epo levels may be increased at birth, they 
decrease rapidly in the following hours in infants with-
out postnatal hypoxia.50 The Iowest Epo values are 
reached during the first 2 months after birth.33 
Thereafter, serum Epo values increase slightly and re-
main constant at levels very similar to those observed 
in adults,33,59 although sorne difference has occasionally 
been noted between children aged 1 to 2 years and chil-
dren aged 4 years or older.60 There appears to be no cor-
relation between Hb and serum Epo in healthy 
children,59 but this is not unexpected for subjects with 
Hb values within the normal range. Inadequate Epo 
production may be encountered in a variety of condi-
tions (Table 1). Similarly to adults, children with chronic 
renal failure have serum Epo levels within the normal 
range or slightly increased, but inappropriately low for 
the degree of anemia.'I-<>3 While nondialyzed patients 
had the highest Hb,61 those on peritoneal dialysis had 
intermediate levels that were significantly higher than 
those in hemodialysis patients because of somewhat 
beller Epo production.63 Epo production is further re-
duced, but certainly not abrogated, in anephric chil-
dren, underlining the role of extrarenal sites in Epo 
production.62 
Serum Epo levels correlate inversely with Hb in chil-
dren with hematological disorders, including aplastic 
anemia, transient erythroblastopenia, iron deficiency 
anemia, or thalassemia.33,64 The slope of the regression 
may be steeper in iron deficiency anemia than in mar-
row erythroblastopenia or pancytopenia, possibly be-
cause the presence of erythroid progenitors could limit 
the elevation of serum Epo in children with less severe 
iron deficiency anemia.64 This inverse relationship was 
maintained in children with acute leukemia, in whom 
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treatment with high-dose chemotherapy produced fur-
ther transient increments of serum Epo levels beyond 
values expe:cted for the degree of anemia.65 However, 
childten with solid tumors have been found to have in-
adequate Epo production in response to anemia.66 
During the first 4 months of life, term infants with 
cyanotic heart disease have significantly higher serum 
Epo concentrations than normal adults and Epo levels 
do not correlate with Hb, arterial oxygen contents, or 
Pa02.67 However, aider children with cyanotic or 
acyanotic congenital heart disease have similar serum 
Epo levels, comparable to those found in normal 
adults.33,68 There was a significant negative correlation 
of serum Epo with arterial oxygen content but not with 
Hb or PaO,.33.68 Therefore, cyanotic children appear to 
initially increase Epo production in response to hy-
poxia until stimulated erythropoiesis increases Hb to 
values ensuring the retum of Epo levels to normal.68 
THERAPEUTIC USES OF rHuEPO IN ADULTS 
After cloning of the gene for Epo, rHuEpo has become 
available for therapeutic use (Table III).69 It has first 
been shown that rHuEpo could correct the anemia of 
chronie renal failure and eliminate the need for trans-
fusion.70 Besides this purely substitutive therapy, a 
number of clinical disorders mOfe or less charaderized 
by defective Epo production have been shown to bene-
fit from treatment with rHuEpo. However, the doses 
necessary ta achieve responses in patient with acquired 
immune deficiency syndrome (AIDS),71 rheumatoid 
arthritis,72 multiple myelorna,73 or other forms of can-
cer" are usually much higher than those used in he-
modialysis patients. The same is true for patients 
undergoing chemotherapy," radiotherapy,75 or bone 
marrow transplantation?' The eflicacy of Epo in treat-
ing the anemia of myelodysplastic syndromes is lim-
ited by the ineflectiveness of erythropoiesis in these 
disorders, whether rHuEpo is used alone71 or in associ-
ation with granulocyte colony-stimulating fador (CSF) 
or other growth factors." rHuEpo has also been pro-
posed in the treahnent of sickle ceIl anemia to increase 
fetal hemoglobin levels." There is also a place for 
rHuEpo in the stimulation of normal erythropoiesis be-
fore elective surgery to avoid transfusions or to in-
crease the preoperative collection of autologous bloodso, 
or bone marrow donation.8l 
TREATMENT OF THE ANEMIA OF CHRONIC 
RENAL FAILURE IN CHILDREN 
As in adults, anemia is a prominent feature of chronic 
renal failure. ln addition to the usual symptoms ob-
served in adults, this anemia also causes retarded 
growth and delayed neurological development in chil-
dren.82 The severity of the anemia is inversely related to 
the glomerular filtration rate." The pathophysiological 
features of the anemia of chronk renal failure in chil-
dren are very similar to those in adults and are mostly 
due to inappropriate Epo production.61--63 However, the 
severity of renal anemia is more pronounced in chil-
dren for several reasons, including the absence of an-
drogen,82 larger blood losses by gastrointesrinal 
bleeding,84 and proportionally more significant blood 
losses in the hemodialysis circuit.84 
Treatment with rHuEpo has been shown to correct 
the anemia of chronic renal failure and eliminate the 
need for transfusion in adult patients?O rHuEpo is also 
TABLE III 
Potential Indications for rHuEpo Therapy in Children 
Indication 
Neonatal anemias 
Anemia of prematurity 
Anemia of bronchopulmonary dysplasia 
Anemia after intrauterine transfusion for 
Rhimmunization 
Anemias of infancy and childhood 
Anemia of chronic renal failure 
AIDSanemia 
Anemia of rheurnatoid arthritis 
Anemia of cancer 
Iatrogenic anemias of infancy and childhood 
Postchemotherapy anemia 
Postoperative anernia 
Postmarrow transplantation anemia 
Other indications 
Sickle œIl anemia 
Congenital heart diseases 
Autologous blood donation 
Bone maITOW donation 
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effective in children on hemodialysis85 or peritoneal 
dialysis.86-88 Epo can be given intravenously usuaUy 
three times weekly,85 subcutaneously either three 
times88 or twice87 or onceB6 a week, or even intraperi-
toneaUy.89 The initial dose is between 75 and 225 
U /kg/wk or probably a little less when the subcuta-
neOllS route is used. The increase in Bct is a150 proba-
bly in part contributed by decreased blood losses 
because of increased platelet counts and function.90 
Once the target Hct has been reached, the dose can usu-
aUy be reduced by one-third to one-haIt. However, oc-
casional patients will need much higher doses. For 
instance after nephrectomy for congenital nephrotie 
syndrome, the response may be very pOOf because 
growth after nephrectomy may be so rapid that even 
Epo-stimulated erythropoiesis is not able to keep up 
with it.91 Correction of the anemia praduces marked 
improvement of cardiac performance92 and exerCÎse 
tolerance,85 which translates into enhanced ability to 
engage in activities. 86 However, little or no effect on the 
growth rate of these children has been noted.'3 The side 
effects of rHuEpa are the same as in adults, the mûst 
prominent being de nova or worsened hypertension.94 
As in adults, the adequacy of iron supplementation is 
critical to the success of therapy.70 . 
OTHER USES OF RHUEPO IN INFANTS 
AND CHILDREN 
Patients with a number of other conditions may benefit 
from treatrnent with rHuEpo (Table JIl). However most 
reports consisted of anecdotal cases or uncontrolled 
studies. Although these indications appear to be 
promising, no general recommendations can be made 
at the present time. 
Multiple intravascular intrauterine transfusions ior 
Rh-immunization suppress prenatal and postnatal ery-
thropoietic activity by limiting Epo production and this 
may result in severe neonatal anemia. 95 This aregener-
ative anemia appearing in the Ist to 3rd month of life 
may respond adequately to treatrnent with 100-200 
U /Kg/ d or rHuEpo.96.97 Patients with the anemia of 
bronchopulmonary dysplasia are not aU born prema-
turely but most of them will respond to 200 U /Kg/ d of 
rHuEpo with increases of reticulocyte counts and Hct 
values.9s 
RHuEpo given at doses up to 2000 U /Kg/ d is inef-
fective in children with Diamond-Blackfan anemia.99 
However, provided iron supplements are given, the re-
sponse of the anemia associated with active juvenile 
rheumatoid arthritis to about 300 U /Kg/wk of rHuEpo 
may be impressive. 1OO 
RHuEpo may also be used to increase red blood 
cel! production in surgery. Very high doses of 500 
U /Kg/ d have been used in children with burned in-
juries!O! but only 40-80 U /Kg/wk were required for 
efficacy in children with persisting aregenerative ane-
IDia after cardiac transplantation.102 The use of 
rHuEpo at doses of 450 U /Kg/wk could be particu-
larly interesting to increase Hct in children undergo-
ing bone marrow donation.SI As Epo deficiency may 
occur after allogeneic bone marrow transplantation, 
delayed erythroid engraftrnent may be treated effi-
ciently with rHuEpo.!03 When Epo is already given at 
a dose of 75 U /Kg/ d immediately after transplant, 
erythroid repopulation is considerably accelerated 
without detrimental effect on myeloid and platelet en-
graftment.!04 FinaUy, cisplatin chemotherapy may be 
complicated by Epo deficiency if a signifieant degree 
of renal failure develops and the subsequent anemia 
may respond to rHuEpo.!OS 
Although this has only been tested in adults with 
sickle cel! anemia, the combination of rHuEpo and hy-
droxyurea may decrease the incidence of vasa-occlu-
sive crises by increasing HbF synthesis.79 Hydroxyurea 
could abrogate the polycythemie effect of rHuEpo, 
which in tum could limit the marrow toxicity of hy-
droxyurea.9 
In infants with congenital heart disease and left-to-
right shunts, the normal decline in Hct after birth re-
sults in congestive heart failure and poor growth. As 
increasing the Hb concentration is associated with re-
duced signs of left-to-right shunt,'06 therapy with 
rHuEpo may therefore bring sufficient clinieal im-
provement to defer surgery until the child reaches an 
ideal weight, but this remains to be demonstrated.9,10ï 
PHYSIOPATHOLOGY OF THE ANEMIA 
OF PREMATURITY 
Among neonates with birth weight <1250 g, 90% re-
quire blood transfusions, on average five, and the prob-
lem is growing because of the improving survival of 
these infants.!OB It is very difficult to determine the pre-
cise indication for blood transfusion in premature in-
fants, as classical signs of anemia may not be as 
relevant.108--110 
There are two types of anemia. The first occurs dur-
ing the first 2 weeks after birth in sick, often ventilated, 
infants requiring intensive care and multiple blood 
tests. llOJll Because of these severe blood losses and the 
time necessary for rHuEpo to become active, treatment 
is less likely to reduce the number of transfusions dur-
ing this period.110,11l This is a problem because of the in-
creased risks associated with blood transfusion in 
premature infants, including viral and bacterial infec-
tions, graft-vs.-host disease, and immune prob-
lems.109,111-113 A second type of anemia, which is called 
the anemia of prematurity, occurs at around 6 weeks 
after birth and is characterized by decreased Hb and a 
failure to compensate by increasing erythropoiesis. 
lndeed, it may be considered as an exaggeration of the 
normal fan of Hb that aU infants experience after 
birth.l08,llU14,115 
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The mean number of circulating BFU-E per nucle-
ated cells between the 19th and 30th week of gestation 
is 3 times higher than in cord blood at birth and 10 
times higher than in adult bane marrow.31 The nUffi-
ber of BFU-E in anemie preterm infants is higher than 
in nonanemic preterm infants or in adults.1l6 Sensiti-
vit Y to Epo is highest in fetal, intermediate in new-
born, and lowesf in adult cultures.1l7 Cord blood 
BFU_E116,118 and marrow CFU-E1l9 from infants with 
the anemia of prematurity are at least as responsive ta 
Epo as are progenîtors from healthy neonates or 
adults. Therefore, the anemia of prematurity does not 
originate frorn abnormalities in the number or func-
tion of erythroid progenitors. 
The pathophysiology of the anemia of prematurity 
is complex (Table IV), but one of the main features is a 
defect in the capacity ta increase Epo synthesis in re-
spanse ta anemia. Although serum Epo levels are nor-
mal or even increased at birth, Epo production 
decreases considerably during the first weeks after 
birth in terrn as well as preterm infants and remains 
low in preterm infants until 6 to 10 weeks before re-in-
creasing ta levels similar to those observed in 
adults.34,109,1l5,120-123 Epo levels are not only inversely re-
lated to Hb concentration but also depend on ils oxy-
gen unloading capacityl09,1l5,120,122,123 so that the best 
correlation is seen with the central venous oxygen ten-
sion.l23 Therefore~ because the Epo response to relative 
hypoxia is based on available oxygen, it rernains inad-
equate for the degree of anernia.l18,120-126 The greatest 
fall fn Hb after birth is observed in the most immature 
infants,Il5 and the Epo response to anemia is blunted to 
a greater extend in the youngest premature infants.uo 
There are a nurnber of reasons for this inappropriate 
Epo production. Epo production is down-regulated by 
the sudden delivery to an atmosphere that is relatively 
hyperoxic cornpared with the intrauterine milieu.126 
Durfng fetallife, the relatively fnsensitive hepatic sen-
TABLE IV 
Physiopathology of the Anemia of Prematurity 
Decreased Hct at birth 
Interrupted Hct increase during fetallife 
Less than optimal placentofetal transfusion at birth 
Loss of red blood cells after birth 
Shorter erythrocyte life span 
Blood sampling for blood tests 
Defective Epo production 
Sudden delivery to hyperoxic environrnent 
Adult-type circulation sending oxygenated blood to 
poorly sensitive hepatic oxygen sensor 
Liver to kidney switch of Epo production not achieved 
Transfusions 
Very rapid growth rate 
Rapidly expanding red cell mass 
Hemodilution 
Limited iron supply 
sor may be sufficient to regulate Epo production fn the 
hypoxic conditions of low arterial PO, and high per-
centage of fetal hemoglobfn. lo8 After premature deliv-
ery and the establishment of an adult-like circulation 
with a large increase in pulmonary blood flow and ar-
terial PO" the hepatic oxygen sensor will shut down 
Epo release until fnfants reach the age at which renal 
production starts.108 The Hb-oxygen dissociation curve 
at birth is shifted to the left because of the high propor-
tion of HbF and low concentration of functional 2,3-
diphosphoglycerate.109,1l5 Later, when an increasing 
proportion of HbA and higher concentration of 2,3-
diphosphoglycerate are produced by the neonate, the 
ensuing reduction fn oxygen affinity will further de-
press Epo production. l22 Blood transfusions will 
worsen the phenomenon by increasfng the total Hb 
level as well as the proportion of HbA.l09,J15 After ces-
sation of transfusions, a temporary rise in HbF is 
seen~127 which may ameliorate the Epo response. 
A number of other fadors may contribute to the ane-
mia of prematurity. As the Hct fncreases durfng fetal 
life, premature infants will have lower values than term 
infants.31 Urgent resuscitation maneuvers may not per-
mit optimal placentofetal transfusion at birth.126 This 
will also reduce the number of circulating erythropoi-
etic progenitors in the preterm newbomP Short ery-
throcyte life span fn the neonate will further be reduced 
in preterm infants by a particular sensitivity to oxida-
tive stress. l26 Blood samplfng for laboratory tests rnay 
be considerable: an 800-g fnfant will lose half of the 
blood volume if 5 to 6 ml ofblood is rernoved daily dur-
ing the 1 week.108,115 As the premature infant has a very 
rapid growth rate, the ensuing expansion of plasma 
volume will further dilute red blood cells. l26 
This accelerated growth requires a rapid expansion 
of the red ceUs mass and large amounts of iron are thus 
needed. Because the fetus accumula tes iron throughout 
pregnancy~U8 iron stores are less adequate in preterm 
infants and particularly in small-for-age premature 
newborns.129 Although the relatively immature gas-
trointestinal tract appears to absorb iron well~130 stores 
may be rapidly exhausted by the enormous demand for 
iron associated with rapid growth and by the negative 
net iron balance presumably due to high fecallosses)30 
Net iron balance will be positive and iron deficiency 
prevented only if sufficient oral or intramuscular iron 
supplements are provided early in life,129-132 
TREATMENT OF THE ANEMIA OF 
PREMATURITY 
Administration of rHuEpo to rhesus monkeys fnduced 
significant increases of hemoglobin in aduIts but no 
change in Hb despite increased reticulocytosis in infant 
monkeys)33 TItis may be due fn part to the larger vol-
ume of distribution, greater clearance and shorter half-
life and residence times in infant cornpared with adult 
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animals.133,134 This has a150 been shown in rnan.135 The 
Epo disappearance rate after birth in neonates without 
hypoxia is faster than in aduIts.50 Another crilical factor 
is iron, which is clearly a rate-limiting factor in erythro-
poiesis during the neonatal periodl36 and even more 50 
during treatment with EpO.133 
There has been much interest in the lise of rHuEpa 
as an alternative ta blood transfusion in infants with the 
anemia of prematurity (Tables V and VI).l07,111,137,!38 A 
European randomized open-label study compared 50 
untreated children with 43 infants treated with 70 
U/kg/wk of rHuEpo. This low dose given for 3 weeks 
starting on day 4 after birth did not produce any effect 
on erythropoiesis.139 An American study of premature 
infants receiving be!ween 10 and 200 U /kg/wk of 
rHuEpo for 4 weeks starting at a median lime of 42 
days after birth obtained increased reticulocyte counts 
and Hct in most infants, with 25% of them still requir-
ing blood transfusions. However, these results are very 
difficult ta interpret because there was no control 
group, and the observed increases were not dose-de-
pendent.140 Halperin and co-workersl26,141 adminis-
tered 75, 150,300, or 600 U/kg/wk of rHuEpo for 4 
weeks starling at a median lime of 27 days after birth. 
There was a dose-dependent elevation of reticùlocyte 
counts and a stabilization of Hct, with only few patients 
requiring transfusions. In comparison, Hct fell and 
blood transfusions were necessary in 20% of 66 histori-
cal control subjects. Shannon et aI.142 randomly treated 
infants with 200 U /kg/wk of rHuEPO or placebo for 6 
weeks starling at a median lime of 22 days after birth. 
Reticulocytes increased earlier, but otherwise there 
were no differences in reticulocyte counts, Hct, or 
transfusion needs between the two groups.142 The same 
group later randomly assigned infants to either placebo 
or 500 U /kg/wk of rHuEpo, with the dose being in-
creased to 1000 U /kg/wk after 2 weeks if target re-
ticulocyte counts were not achieved. Treatment was 
given for 6 weeks starling on day 10 to 35 after birth. 
Reticulocytes increased significantly more in the 
treated group, Hct remained stable in the treated group 
but fell in the placebo group, and transfusions were less 
required in treated versus placebo infants.143 In a ran-
domized open-label study, Ohis and Christensen144 
compared the efficacy of transfusions with that of 700 
U/kg/wk of rHuEpo for 3 weeks starting at a median 
lime of 41 days after birth. As expected, transfusions 
were more efficacious in rapidly rising the Hct, but 
reticulocytes increased more in the rHuEpo-treated 
group and at the end ofthe study, the Hel was very sim-
ilar in the two groups. Carnielli et al,145, randomly as-
signed infants to receive either no treatment or 1200 
U /kg/wk of rHuEpo from day 2 after birth unlil dis-
charge. Contrary to other studies, control subjects were 
not given iron supplements. Reliculocytes and Hct fell 
in control subjects, while reticulocytes încreased more 
and Hct stabilized in the treated group, resuIting in 
fewer transfusions administered. However, the criteria 
for ordering red cell transfusion were very liberal. 
Ernmerson et aJ.146 conducted a randomized double-
blind study comparing placebo with rHuEpo at the 
dose of 100, 200, or 300 U /kg/wk from day 7 after birth 
until discharge. There were definite signs of more ac-
tive erythropoiesis in infants receiving rHuEpo. 
Approximately twice as many infants receiving 
placebo required red cell transfusions, resulling in the 
end in similar declines of Hel values throughout the 
study in the Iwo groups. Bechensteen et al.!47 compared 
no treatment with 300 U /kg/wk of rHuEpo for 4 weeks 
starting on day 21 after birth. Compared with control 
subjects treated patients had higher reliculocyte counts 
and maintained their Hct, and none (vs. 4 of 15 control 
subjects) required red cell transfusions,147, In a large 
study conducted by Messer et aJ.148 infants were con-
secutively assigned to three treatment groups receiving 
300,600, or 900 U /kg/wk of rHuEpo for 6 weeks start-
ing on day 10 after birth. Infants whose parents did not 
consent to the study served as control subjects, 
Reticulocytes increased more and in a dose-dependent 
fashion in treated infants, while Hct decreased less al-
beit without a clear dose-response effect. This resulted 
in significantly fewer blood transfusions. 
Many differences among these clinical trials make 
comparison between them and definite conclusions 
difficult to derive. Smaller infanls are sicker, and thus 
probably less responsive to rHuEpo and require more 
blood sampling for laboratory tests, which may hide 
the beneficial effect of treatment.142,143 However, as they 
receive the largest number of transfusions, the smallest 
infants are the most likely to benefit from effective ther-
apy)38 Liberal transfusion criteria will overstate the 
benefit of rHuEpo, not only because more transfusions 
will be given, but also because repeated transfusions 
will suppress the endogenous Epo response to ane-
mia.145 As the anemia of prernaturity is an exaggeration 
of the fall of hemoglobin that ail infants undergo dur-
ing the first month of life,115 il should not be expected 
that treatrnent in the first week after birth would in-
crease the Hct139,145,146,148 but would only slow its 
fall,145,146,148 while late treatment could produce signifi-
cant increments.!40,14' Doses <300 U /kg/wk will not 
bring about significant changes in erythropoietic activ-
ity.139-142 Establishing the appropriate dose and route of 
supplementary iron remains an open question. The 
highest doses of iron supplements are associated with 
the best responses to rHuEpo.141,143J47,148 We do not 
know what dose of iron can be safely administered en-
terally or intravenously to premature babies and 
whether treatment should be discontinued if storage 
iron falls below sorne criticallevel because iron is ab-
solutely required for cell division in many organs,138 
The tolerance to rHuEpo has been excellent and no 
serious side effects have been attributed to treatrnent. 




Treatment of the Anemia of Prematurity with rHuEpo: Study Characteristics 
No. Gestational age Age Dose Duration Oral iron 
Author Year treated (wk)* (days)' (U/kg/wk) Route (wk) (mg/kg/day) Design 
Obladen 1991 43 30 (28-32) 4 70 SC 3 2 Randomized, open-label trial 
(50 controls) 
Beek 1991 16 29 (27-32) 42 (25-59) 10-200**+ IV 4 3 Open-label trial (no con troIs) 
Halperin 1992 18 31 (28-33) 27 (21-33) 75-600**t SC 4 2~8*t Open-label Trial 
(66 historical controls) 
Shannon 1991 10 27 (<33) 22 (10-35) 200 IV 6 3 Randomized, placebo-controlled 
trial (10 controls) 
Shannon 1992 4 27 (25-29) 19 (8-28) 500-1000**1 SC 6 3-6***+ Randomized, placebo-controlled 
trial (4 controls) 
OhIs 1991 10 28 (26-30) 41 (21-70) 700 SC 3 2 Randomized ta received 
3§ 
transfusion (n = 9) or rHuEpo 
CarnieIli 1992 11 30 (25-32) 2 1200 IV Ta discharge Randomized, open-label trial 
(11 controls) 
Emmerson 1993 15 30 (27-33) 7 100-300 SC To discharge 6 Randomized, placebo-controlled 
trial (8 controls) 
Bechensteen 1993 14 30 (27-31) 21 300 SC 4 18 Randomized, open-label trial 
(15 controls) 
Messer 1993 31 30 «33) 10 300-900 SC 6 3-15; Open-label trial 
(20 concomitant contraIs) 
""Mean (range). 
**tDose escalation in groups of infants. 
**:j:Dose escalation in same patients. 
'IV. 
TABLE VI 
Treatment of the Anemia of Prematurity with rHuEpo: Results 
Transfusions 
(No. transfused/ SeFe or Tf 
Authar Year Reticulocytes Hb/Hct No. evaluable) Ferritin saturation Neutrophils Platelets Comments 
Obladen 1991 Stable Decrease in bath 23/45 Stable NA Stable Increase in 
groups bath groups 
Beek 1991 Non-dose- Non-dose- 4/16 Decrease Decrease Transient Mild increase 
dependent dependent decrease in sorne 
increase increase 
Halperin 1992 Dose-dependent Stable in rHuEpo, 3/18 Decrease Decrease Late decrease in Transient Increased HbF; stable 
increase decrease in con troIs sorne increase BFU-E; nonsignificant 
decrease of CFU-GM 
Shannon 1991 Earlier increase Decrease in both 6/10 NA NA Stable Stable No cffeet on HbF due 
inrHuEpo groups (8/10 in controls) ta large transfusions 
Shannon 1992 Larger increase Stable in rHuEpo; 1/4 Decrease Stable Stable Stable Increased HbF 
in rHuEpa decrease in controis (3/4 in contraIs) 
OhIs 1991 Larger increase Faster increase in Decrease NA Decrease more in Stable Increased marrow 
inrHuEpo transfused rHuEpo erythroblasts and 
CFU-E; stable 
BFU-E and CFU-GM 
Carnielli 1992 Larger increase Stable in rHuEpo; 0.8 per infant NA NA Stable Stable 
in rHuEpa decrease in controls (3.1 in controls) 
Emmerson 1993 Larger increase Decrease in both 7/15 Decrease NA Stable Stable Increased HbF 
inrHuEpo groups (7/8 in controls) 
Bechensteen 1993 Larger increase Stable in rHuEpa; 0/14 Decrease Decrease Stable Stable 
inrHuEpo decrease in controls (4/15 in controls) 
Messer 1993 Dose-dependent Smaller decrease in 6/31 NA Decrease Stable Stable 
increase rHuEpo (9/20 contraIs) 
SeFe, serum iron; Tf, transferrin; NA, not available. 
g; 
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has been ohserved in uncontrolled studies,l40,141,144 this 
complication has not been encountered in larger or ran-
domized trials.139,142,145,147,148 Administration of very 
large doses of Epo to newbom rats resulted in reduced 
numbers of marrow and spleen CFU-gramùocyte-
macrophage and dirninished neutrophil production.!49 
However, studies in serum-fee culture systems in the 
presence of interleukin 3, granulocyte-macrophage 
CSF, and granulocyte CSF alone or in combination, pro-
vided no evidence for a detrimental effect of Epo on 
myelopoiesis.150 
CONCLUSIONS ON THE USE OF rHuEPO IN 
INFANTS AND CHILDREN 
Many indications for rHuEpo accepted in adults may 
also be valid in children. Provided that adequate iron 
supplements are given, erythropoietin at doses of 100 
to 300 U/Kg/wk is very effective in coITecting fhe ane-
mia of chronie renal failure in patients on dialysis or 
not. It is now clear that rHuEpa is very effective in stim-
ulating erythropoietic activity in infants wifh the ane-
mia of prematurity. Whether this stimulation of 
erythropoiesis will translate inta increased Het and a 
reduction in transfusion needs depends on the age of 
the infants, the dose used (at least 300 U/Kg/wk), the 
adequacy of iron supplementation (at least 6 
mg/kg/day), and the importance of concomitant 
blood sampling for laboratory tests. Despite interesting 
efficacy in sorne pilot studies, the limited experience 
obtained 50 far precIudes general recornmendations for 
the use of rHuEpa in other forms of an~mia, such as the 
late postnatal anemia caused by intrauterine transfu-
sions, the anemia of bronchopulmonary dysplasia, the 
anemia of chronic juvenile arthritis, the anemia associ-
ated with bone marrow donation or transplantation or 
with bum injuries or surgery. The role of rHuEpo in in-
creasing the Hel of infants with congenital heart dis-
ease and left-to-right shunt or in stimulating the 
production of fetal Hb in children with sickle cell ane-
mia should be investigated. Unless the critical role of 
adequate iron supplementation is recognized, absolute 
functional iron deficiency willlimit the efficacy of any 
treatment with rHuEpo. In that regard intravenous iron 
will be more efficient than orally administered iron, but 
ils safety in children is not yet weU established. 
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